Paulukonis Susan T, Horiuchi Sophia, Austin Tomia, Vichinsky Elliott P
Tracking California Program, Public Health Institute, Oakland, CA, USA.
As One Foundation, Katy, TX, USA.
Public Health Rep. 2025 Sep 11:333549251361764. doi: 10.1177/00333549251361764.
Sickle cell trait (SCT) is the carrier status for sickle cell disease, and people with SCT have both hemoglobin A (HbA) and sickling hemoglobin (HbS). SCT is generally regarded as a benign condition, but clinical complications can be substantial. No registry or surveillance system exists to track health outcomes for people with SCT; this study aimed to identify methodology for surveillance.
This longitudinal analysis included all live births with SCT identified by the California Department of Public Health Newborn Screening (NBS) Program from 1991 through 2013 and 3 matched controls per newborn, linked to death data in California for 1991-2013.
There were 94 240 live births with SCT and 282 720 matched healthy controls; 693 (0.74%) deaths occurred in the SCT group, and 1910 (0.68%) deaths occurred among the matched controls. Those with SCT had an increased mortality hazard ratio (MHR) compared with matched controls (11% higher; = .02). When stratified, the MHR was higher among those aged 1 to 4 years (44% higher; < .001) and 5 to 14 years (48% higher; = .005) than among the matched controls. Examination of causes of death showed only a slightly higher-than-expected risk of death due to respiratory causes among people with SCT.
These findings highlight the need for population-level research, including investigation into causes of death, to inform clinical management and counseling for SCT. Other states may replicate this methodology with population-based data sources. Further surveillance of the health of those with SCT is needed.
镰状细胞性状(SCT)是镰状细胞病的携带状态,患有SCT的人同时拥有血红蛋白A(HbA)和镰状血红蛋白(HbS)。SCT通常被视为一种良性病症,但临床并发症可能相当严重。目前尚无登记或监测系统来跟踪SCT患者的健康结局;本研究旨在确定监测方法。
这项纵向分析纳入了1991年至2013年间加利福尼亚州公共卫生部新生儿筛查(NBS)项目确定的所有患有SCT的活产婴儿,以及每名新生儿匹配的3名对照,并与1991 - 2013年加利福尼亚州的死亡数据相链接。
有94240例患有SCT的活产婴儿和282720名匹配的健康对照;SCT组有693例(0.74%)死亡,匹配对照组有1910例(0.68%)死亡。与匹配对照组相比,患有SCT的人死亡风险比(MHR)有所增加(高11%;P = 0.02)。分层后,1至4岁(高44%;P < 0.001)和5至14岁(高48%;P = 0.005)的SCT患者的MHR高于匹配对照组。对死亡原因的检查显示,SCT患者因呼吸系统原因导致的死亡风险仅略高于预期。
这些发现凸显了开展人群层面研究的必要性,包括对死亡原因的调查,以为SCT的临床管理和咨询提供依据。其他州可以利用基于人群的数据源复制这种方法。需要对SCT患者的健康进行进一步监测。